Stereotactic body radiotherapy for isolated paraaortic lymph node recurrence from colorectal cancer

Table 1 Demographic data of 7 patients

Patient No.	Age (yr)/Sex	Latent time (mo)	GTV (mL)	Dose (Gy)	Prescribed isodose (%)	Dmax of intestine (Gy)	V45 (mL)	Failure pattern	F/U (mo)	Final status
1	63/M	9	20	36	83	33	0	Lt SCLN (23)	70	AWD
								Lung (32)
2	64/F	44	4	41	82	38	0	-	37	Died due to lymphoma
3	52/F	29	24	45	78	48	0.2	Spine (26)	41	DOD
4	59/M	21	22	48	80	51	0.7	Lung (7)	22	DOD
5	56/M	10	9	48	80	40	0	PALN(9)	21	AWD
6	47/M	18	40	48	76	53	3.6	Rectum (7)	25	DOD
								Lt SCLN (7)
								Peritoneal seeding (25)
								Local recur (13)
7	73/M	7	29	51	78	50	0.9	-	26	CDF

GTV: Gross tumor volume; AWD: Alive with disease; CDF: Continuously disease-free; DOD: Died of disease; Latent time: Disease free interval from operation to first relapse; F/U: Follow-up from commencement of SBRT to last follow-up or death; Lt SCLN: Left supraclavicular lymph node; Dmax: Maximum point dose of intestine; V45: Intestinal volume receiving 45 Gy or more; Vpre: Total volume receiving the prescribed dose or more; Parenthesis (mo) means the period from SBRT to detection of complication.

Table 2 Comparison of survival for recurrence from CRC treated by surgery or other treatment method

Study	Failure site	Treatment	n	Median survival (mo)	Survival rate (yr)
Gwin et al[15], 1993	Non-hepatic intra-abdominal	R01	15	25.5	60 (2), 0 (3)
		R12	6	8	34 (2), 34 (3)
		R23	7	3.5	15 (2)
Shibata et al[13], 2002	Retroperitoneum	R0	15	81	56 (5)
		R1	5	29	0 (5)
		R2	4	3	0 (5)
Bowne et al[14], 2005	Retroperitoneum	R0	8	44	NA
		R1	8
Min et al[12], 2008	PALN	R0	6	34	80 (3), 0 (5)
		Chemotherapy4	33	12	18 (3), 7 (5)
Present study	PALN	SBRT	7	41	71.4 (3)

¹Curative resection;

²Marginal resection;

³Incomplete, bypass or colostomy;

⁴Resection is not planned. CRC: Colorectal cancer; PALN: Paraaortic lymph node; SBRT: Stereotactic body radiotherapy; NA: Not assessed.